Prothena Corporation plc (PRTA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Prothena Corporation plc stock $5.24, price $7.97, that is 34.3% below the price, quality 40 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range $4.58 – $78.89 · fair‑value band $3.46 – $6.55 · the $7.97 price screens above the $5.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Prothena Corporation in your weekly email
Every Wednesday you see whether Prothena Corporation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
Show moreShow less
Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.
In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease.
It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Stock analysis
Prothena Corporation plc (PRTA) currently trades at $7.97, while our model-based Fair Value estimate is $5.24, 34% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $3.46 (bear) to $6.55 (bull), the price of $7.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Prothena Corporation plc reported revenue of $9.7M in FY2025 versus $201M in FY2021, a compound −53.1%/yr. Reported net income was −$244M in FY2025.
Key figures
Market cap $416M Small · P/S ratio 7.76 · EPS (TTM) $−0.8200 · Return on equity −8.5% · Return on assets (EBIT) −23.5% (5-year average) · Operating margin −2,968% · Revenue growth (YoY) −74.3% · Free cash flow −$164M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 31% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −34%, PRTA screens richer than that median.
Fair Value models
Bear$3.46Fair Value $5.24Bull$6.55
Price $7.97 · Downside -34.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 2 officers or directors sold shares worth $135,927 and none bought.
BuyWilliam P Scully10% owner15× since May 22, 2026: 1,400,000 shares, avg. $8.63$12.1MOct 23, 2026
SaleMichael John IsaacsGeneral Counsel & Company Sec.8,386 shares at $8.47$71,029Jul 29, 202610b5-1 plan
SaleAnne Evans KingstonChief Strategy Officer7,662 shares at $8.47$64,897Jul 29, 202610b5-1 plan
Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−92.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−43.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.6%
Start year 2020 (pandemic). Over 10 years: +19.7% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−13,216.2% (2020) → −1,905.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Compare Prothena Corporation plc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−34.3% · Above median
Profitability
Return on assets−74.7% · Bottom 25%
Net margin (12 months)−45.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−74.3% · Bottom 25%
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.48× · Cheaper than median
P/S (12 months)7.88× · Pricier than median
PEG0.80× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)94· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Prothena Corporation plc (PRTA) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $5.24 versus a price of $7.97, about 34% lower (overvalued).
What is the fair value of PRTA?
Our model-based fair value for Prothena Corporation plc is $5.24 (as of Nov 7, 2026), built from audited fundamentals. The current price: $7.97.
What is the quality score of PRTA?
Prothena Corporation plc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prothena Corporation plc (PRTA)?
Our model-based price target is the fair value of $5.24 (as of Nov 7, 2026) from 1 valuation models. Cautious scenario $3.46, optimistic scenario $6.55. It is a calculation from audited fundamentals, not an analyst target.
What is the Prothena Corporation plc stock forecast for 2026?
Our models put fair value at $5.24, about 34% lower versus a price of $7.97 (overvalued). Cautious scenario $3.46, optimistic scenario $6.55. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Prothena Corporation plc (PRTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prothena Corporation plc it is $5.24 per share (as of Nov 7, 2026), against a price of $7.97. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Prothena Corporation plc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, PRTA trades above its calculated fair value: price $7.97, fair value $5.24, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRTA?
No. The price is what the market pays today ($7.97); the fair value is what the company's own numbers justify ($5.24). For Prothena Corporation plc the two are $2.73 per share apart. That gap is exactly why we show both numbers side by side.
How much is Prothena Corporation plc worth?
The market values Prothena Corporation plc at about $416M (market capitalisation, as of Nov 7, 2026). Per share that is $7.97; our models calculate a fair value of $5.24 per share.
What do the bullish and bearish scenarios say about PRTA?
Our models span a range for Prothena Corporation plc: cautious scenario $3.46, base $5.24, optimistic $6.55 per share (as of Nov 7, 2026, price $7.97). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of PRTA?
The PEG ratio of Prothena Corporation plc is 0.80 (P/E divided by earnings growth, as of Nov 7, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Prothena Corporation plc (PRTA)?
Balance-sheet figures for Prothena Corporation plc (as of Nov 7, 2026): return on equity −8.5%, debt of 0.13 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is PRTA from its 52-week high?
Prothena Corporation plc trades at $7.97, about 31% below its 52-week high of $11.51 and 1% above the low of $7.89 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.24 is for.
Which stocks are comparable to Prothena Corporation plc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prothena Corporation plc stock attractive at the current price?
The data as of Nov 7, 2026: price $7.97, calculated fair value $5.24 (−34%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRTA calculated?
We run Prothena Corporation plc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $5.24 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Prothena Corporation plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prothena Corporation plc (PRTA)?
The closing price on Nov 6, 2026 was $7.97. Our model-based fair value is $5.24, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prothena Corporation plc right now?
The price sits above even our optimistic bull case ($6.55). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($3.46 to $6.55) leaves room in how you read the outcome.
Key figures of Prothena Corporation plc
How large is the market capitalisation of Prothena Corporation plc (PRTA)?
The market capitalisation of Prothena Corporation plc is $416M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prothena Corporation plc (PRTA)?
The price-to-sales ratio of Prothena Corporation plc is 7.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Prothena Corporation plc (PRTA)?
Earnings per share at Prothena Corporation plc are $−0.8200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Prothena Corporation plc (PRTA)?
The return on equity (ROE) of Prothena Corporation plc is −8.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prothena Corporation plc (PRTA)?
On an EBIT basis the return on assets of Prothena Corporation plc is −23.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prothena Corporation plc (PRTA)?
The operating margin of Prothena Corporation plc is −2,968% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prothena Corporation plc (PRTA)?
Revenue at Prothena Corporation plc is growing −74.3% versus a year earlier (3y avg −43.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Prothena Corporation plc (PRTA) generate?
The free cash flow of Prothena Corporation plc is −$164M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Prothena Corporation plc (PRTA) hold?
Prothena Corporation plc holds more cash than debt, $294M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Prothena Corporation plc in the live analysis
One click puts Prothena Corporation plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026
